Chinese pioneer of orthopedic and spine surgical robots that guide implant placement during surgery.
Chinese pioneer of orthopedic and spine surgical robots that guide implant placement during surgery.
Sells surgical robots to hospitals as large capital purchases, so sales depend on hospital equipment budgets and approvals in China. Surgeon training and procedure volumes decide whether installed robots keep being used and justify further purchases.
In one line: A Chinese Mazor Robotics/Stryker Mako for orthopedic surgery robotics.
Moat: narrow (IP / patents, regulatory licence). First-mover Chinese approvals and patented navigation robotics create an early lead.
Headquarters: Beijing, China · Founded: 2005 · Employees: 334
Size Tinavi Medical Technologies (688277.SS) is a China Health Care company (Medical Specialties) with a market value of $872M, the 2429th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.62 on 18 Nov 2026.
Performance Over six months the shares fell 36.5%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 2.3% over the last twelve months (peer median +10.4%); the operating margin is -58.7% (peer median 10.0%).
Valuation It trades at 21.7× enterprise value to sales against a peer median of 3.5× (most expensive of 21).
Capital Return on invested capital runs 16.0 points below its cost of capital (8.5% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥268M | CN¥279M | CN¥179M | CN¥209M | CN¥156M |
| Revenue growth | — | +56% | -15% | +34% | — |
| Gross profit | CN¥188M | CN¥156M | CN¥99.3M | CN¥121M | CN¥85.1M |
| EBITDA | n/a | -CN¥131M | -CN¥115M | -CN¥167M | -CN¥125M |
| Net income | -CN¥164M | -CN¥183M | -CN¥121M | -CN¥156M | -CN¥111M |
| Free cash flow | -CN¥203M | -CN¥85.0M | -CN¥135M | -CN¥395M | -CN¥144M |
| Capital expenditure | CN¥29.6M | CN¥29.7M | CN¥36.7M | CN¥221M | CN¥59.6M |
| Total debt | CN¥207M | CN¥197M | CN¥199M | CN¥220M | CN¥98.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tinavi Medical Technologies 688277.SS | $872M | -36% | -2% | -59% | 21.7× | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 4.0× | 9.1% |
| Stryker SYK | $121B | -1% | +8% | 25% | 5.1× | 10.7% |
| Beijing Balance Medical Technology 688198.SS | $1.31B | -32% | +10% | 28% | 13.4× | 20.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688277.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.4% | -8.0% | 6th lowest of 21 |
| 6-month return | -36.5% | -15.1% | 4th lowest of 21 |
| Distance from 52-week high | -56.6% | -41.9% | 6th lowest of 21 |
| Revenue growth (TTM) | -2.3% | +10.4% | 4th lowest of 21 |
| Operating margin | -58.7% | 10.0% | 2nd lowest of 21 |
| EV / Sales | 21.7× | 3.5× | most expensive of 21 |
| ROIC minus cost of capital | -16.0 pp | +2.0 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | 21.7× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 7.2× | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 10.4× | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 3.3× | 16.8% | +2.9% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 3.1× | 2.0% | +12.7% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 13.7× | 37.6% | +12.4% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | 12.0× | 11.1% | +4.6% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 4.0× | 19.3% | +23.3% |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 2.0× | 7.5% | +12.1% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 1.6× | -7.1% | +11.3% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 0.7× | -14.6% | -1.3% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 2.6× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 5.5× | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 1.0× | -6.4% | +6.6% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | 3.4× | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | 6.8× | 35.6% | +17.1% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | 9.6× | n/a | n/a |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 3.6× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 3.0× | 20.0% | +21.4% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | 9.7× | 32.6% | +21.0% |